Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in Merkel cell carcinoma

H Sihto, H Kukko, V Koljonen, R Sankila, T Böhling… - Clinical Cancer …, 2011 - AACR
H Sihto, H Kukko, V Koljonen, R Sankila, T Böhling, H Joensuu
Clinical Cancer Research, 2011AACR
Purpose: Merkel cell carcinoma (MCC) is rare skin cancer that is often associated with
Merkel cell polyomavirus (MCPyV) infection. Polyomaviruses repress tumor suppressor
proteins, thus influencing cell-cycle progression, but the effect of MCPyV on the key cell-
cycle regulating proteins is poorly understood. Experimental Design: We evaluated
expression of the MCPyV large T-antigen (LTA), Ki-67, and the key putative tumor
suppressor proteins, the retinoblastoma protein (RB and phospho-RB) and p53, and their …
Abstract
Purpose: Merkel cell carcinoma (MCC) is rare skin cancer that is often associated with Merkel cell polyomavirus (MCPyV) infection. Polyomaviruses repress tumor suppressor proteins, thus influencing cell-cycle progression, but the effect of MCPyV on the key cell-cycle regulating proteins is poorly understood.
Experimental Design: We evaluated expression of the MCPyV large T-antigen (LTA), Ki-67, and the key putative tumor suppressor proteins, the retinoblastoma protein (RB and phospho-RB) and p53, and their regulatory proteins (cyclin D1, cyclin E, p16, p21, p27, and MDM2) by using immunohistochemistry from tumors of 91 MCC patients identified from a population-based nationwide cohort. Tumor MCPyV DNA was measured by using quantitative PCR, and TP53 mutations were identified with sequencing.
Results: MCPyV LTA expression was strongly associated with presence of MCPyV DNA in tumor, and it was almost invariably associated with tumor RB expression (P < 0.0001 for both comparisons). Both MCC LTA and RB expression were strongly associated with favorable MCC-specific and overall survival in univariable analyses (P ≤ 0.01 for all four analyses). Presence of MCPyV LTA was also associated with the female gender, the intermediate type of tumor histology, location of the tumor in a limb, cell proliferation rate, and absence of p53 expression. TP53 mutations were detected only in MCPyV DNA–negative tumors.
Conclusions: MCPyV DNA–positive MCC has several clinical and molecular features that differ from MCPyV DNA-negative cancers. MCPyV-associated MCCs express RB, but may not harbor TP53 mutations. These findings provide further support that MCPyV causes the majority of MCCs. Clin Cancer Res; 17(14); 4806–13. ©2011 AACR.
AACR